Detalhe da pesquisa
1.
Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Invest New Drugs
; 40(1): 163-171, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351518
2.
Association of Planning Target Volume with Patient Outcome in Inoperable Stage III NSCLC Treated with Chemoradiotherapy: A Comprehensive Single-Center Analysis.
Cancers (Basel)
; 12(10)2020 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33086481
3.
Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
Anticancer Res
; 40(4): 2319-2322, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32234932
4.
Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
Radiat Oncol
; 15(1): 148, 2020 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32517716
5.
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Radiat Oncol
; 15(1): 5, 2020 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31898519
6.
Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
Anticancer Res
; 39(9): 5077-5081, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31519618
7.
Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy.
Transl Lung Cancer Res
; 8(5): 593-604, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31737496